Sumatriptan

Drug #696

Sumatriptan (Succinate) is a 5-HT 1 agonist. Sumatriptan (Succinate) is given orally or parenterally in acute migraine attacks. It reduces the dilatation of blood vessels associated with throbbing headache. Sumatriptan (Succinate) is not for the prophylaxis of migraine.

← Previous drug Next drug →

Primary Characteristics

Sumatriptan is also known as Sumatriptan (Succinate).

It is of Synthetic origin and belongs to Sulphonamide.

It belongs to 5HT-1 agonist pharmacological group on the basis of mechanism of action and also classified in Serotonin 5HT1D Receptor Agonist pharmacological group. It is also classified under Antimigraine .

Molecular Weight: 413.5 · Solubility in Water: 1 in 10 · Solubility in Alcohol: null · Non-proprietary name: Sumatriptan (Succinate).

Pharmacokinetics

Absorption: Sumatriptan has an oral bioavailability is 50% (±50%), pre-systemic (first-pass) metabolism accounts for 73% (±2%).

Distribution: Sumatriptan has a volume of distribution is 170 litre. plasma protein binding is 14-21%.

Elimination: it is metabolised via MAO, plasma half-life is 2 hr, renal excretion is 60% urine,40% feaces.

Indications

Sumatriptan is primarily indicated in conditions like Cluster headache, Migraine, Treatment of acute migraine attacks.

Contraindications

Sumatriptan is contraindicated in conditions like Diabetes mellitus, Hypertension, Myocardial infarction, Peripheral vascular disease, Ischaemic heart disease, Cerebrovascular accident, Prinzmetal's angina, Hepatic impairment, Coronary artery disease, Hypersensitivity.

Dosage

Sumatriptan's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
50 mg	50 mg	Every 8h	PO	Should be given as early as possible after the onset of a migraine headache. If a patient does not respond to the first dose, a second dose should not be taken for the same attack.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown4 interactions

3 interactions

Major8 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Sumatriptan in overdosage may give rise to further complications which include Cardiac arrhythmias, Bradycardia , AV-block , Nystagmus , Angina , Atrial fibrillation , Tachycardia , Ventricular fibrillation , Syncope , Seizures , Ventricular tachycardia , Sinus bradycardia , Ischemic colitis, Hypertensive crises , Myocardial infarction .

Sumatriptan produces potentially life-threatening effects which include Myocardial Ischemia . Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Sumatriptan are Diarrhea, Dyspnea, Myalgia.

Sumatriptan is known to cause more or less tolerable side effects which are usually transient. These include Diplopia, Dizziness, Drowsiness, Fatigue, Flickering, Flushing, Heat sensation, Heaviness, Irritation, Muscle cramps, Nausea and vomiting, Pain , Palpitation, Pressure or tightness in body parts, Reduced vision, Tingling , Vertigo, Weakness.

Warnings / Precautions

Sumatriptan should be used with caution in patients with any pre-existing heart disease, coronary artery disease, high blood pressure, stroke, abnormal heart rhythm, kidney disease, liver disease or if have any allergy especially to sulfa drugs. Since this may cause drowsiness, use caution while driving or engaging in activities requiring alertness, avoid alcohol because it may increase drowsiness or dizziness effects. Sumatriptan should be used during pregnancy or lactation only when clearly needed. The drug should only be used where there is a clear diagnosis of migraine. Before treating headaches in patient not previously diagnosed as migrainures, and in migrainures who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should be noted the migranures may be at increasd risk of certain cerebrovascular events. The drug should be used with caution in the patient with the history of epilepsy or structural brain lesions which lower their convulsion threshold. The recommended dose of sumatriptan should not be exceeded.

Interference in Pathology

Sumatriptan may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

6 mg

Tabs

100 mg 25 mg 50 mg

Multi-Ingredient Combinations

Tabs

85 mg

Storage Conditions

Sumatriptan should be stored Tab, Inj, Nsal Spray.

Drug Classification

1.7.1 — Acute migraine attack

Manufacturers

Manufacturers of Sumatriptan in Pakistan:

Atco Genix GSK Hilton Platinum S.J.& G Shrooq Wilshire